Kalaris Therapeutics, Inc. (KLRS)
NASDAQ: KLRS · Real-Time Price · USD
5.64
-0.38 (-6.40%)
At close: Apr 28, 2026, 4:00 PM EDT
5.62
-0.02 (-0.33%)
After-hours: Apr 28, 2026, 4:07 PM EDT

Kalaris Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22
Selling, General & Admin
15.46.691.762.24
Research & Development
30.7545.0411.7111.76
Operating Expenses
46.1551.7313.4614.01
Operating Income
-46.15-51.73-13.46-14.01
Interest Expense
-1.63-40.72-1.58-1.03
Other Non Operating Income (Expenses)
4.3423.280.340.75
EBT Excluding Unusual Items
-43.44-69.17-14.7-14.29
Other Unusual Items
----1.2
Pretax Income
-43.44-69.17-14.7-15.49
Net Income
-43.44-69.17-14.7-15.49
Net Income to Common
-43.44-69.17-14.7-15.49
Shares Outstanding (Basic)
15164
Shares Outstanding (Diluted)
15164
Shares Change (YoY)
1042.87%-77.99%36.56%-
EPS (Basic)
-2.85-51.77-2.42-3.48
EPS (Diluted)
-2.85-51.77-2.42-3.48
Free Cash Flow
-38.57-20.67-14.13-9.78
Free Cash Flow Per Share
-2.53-15.47-2.33-2.20
EBITDA
-46.14---
D&A For EBITDA
0.01---
EBIT
-46.15-51.73-13.46-14.01
Source: S&P Capital IQ. Standard template. Financial Sources.